date,title,source
Oct-18-18,"Trovagene to Provide Update on Onvansertib Clinical Development Program on Wednesday, October 24, 2018",PR Newswire
Oct-24-18,Trovagene Announces New Patent Claim Allowances Affirming Broad Patent Portfolio Coverage of NPM1 Mutations by U.S. Patent and Trademark Office,PR Newswire
Nov-01-18,Trovagene to Present Data from Lead Clinical Program of Onvansertib in Acute Myeloid Leukemia at the 60th American Society of Hematology Annual Meeting,PR Newswire
Nov-07-18,Trovagene Announces Third Quarter 2018 Highlights and Financial Results,PR Newswire
